108 related articles for article (PubMed ID: 3825176)
1. Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver.
Andersson P; Lihné M; Thalén A; Ryrfeldt A
Xenobiotica; 1987 Jan; 17(1):35-44. PubMed ID: 3825176
[TBL] [Abstract][Full Text] [Related]
2. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects.
Thalén A; Brattsand R; Andersson PH
Acta Derm Venereol Suppl (Stockh); 1989; 151():11-9; discussion 47-52. PubMed ID: 2624062
[TBL] [Abstract][Full Text] [Related]
3. In vitro biotransformation of glucocorticoids in liver and skin homogenate fraction from man, rat and hairless mouse.
Andersson P; Edsbäcker S; Ryrfeldt A; von Bahr C
J Steroid Biochem; 1982 Jun; 16(6):787-95. PubMed ID: 7109582
[TBL] [Abstract][Full Text] [Related]
4. Metabolic pathways of the topical glucocorticoid budesonide in man.
Edsbäcker S; Jönsson S; Lindberg C; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1983; 11(6):590-6. PubMed ID: 6140145
[TBL] [Abstract][Full Text] [Related]
5. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects.
Edsbäcker S; Andersson P; Lindberg C; Paulson J; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1987; 15(3):403-11. PubMed ID: 2886319
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation rate (in vitro) and systemic potency (in vivo) of the topical glucocorticoid budesonide in male and female rats.
Andersson P; Brattsand R; Edsbäcker S; Källström L; Ryrfeldt A
J Steroid Biochem; 1982 Dec; 17(6):703-6. PubMed ID: 7176660
[TBL] [Abstract][Full Text] [Related]
7. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
Moore CD; Roberts JK; Orton CR; Murai T; Fidler TP; Reilly CA; Ward RM; Yost GS
Drug Metab Dispos; 2013 Feb; 41(2):379-89. PubMed ID: 23143891
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.
Ryrfeldt A; Andersson P; Edsbäcker S; Tönnesson M; Davies D; Pauwels R
Eur J Respir Dis Suppl; 1982; 122():86-95. PubMed ID: 6958498
[TBL] [Abstract][Full Text] [Related]
9. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids.
Brattsand R; Thalén A; Roempke K; Källström L; Gruvstad E
J Steroid Biochem; 1982 Jun; 16(6):779-86. PubMed ID: 7109581
[TBL] [Abstract][Full Text] [Related]
10. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities.
Brattsand R; Thalén A; Roempke K; Källström L; Gruvstad E
Eur J Respir Dis Suppl; 1982; 122():62-73. PubMed ID: 6958495
[TBL] [Abstract][Full Text] [Related]
11. Metabolic acetal splitting of budesonide. A novel inactivation pathway for topical glucocorticoids.
Edsbäcker S; Andersson P; Lindberg C; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1987; 15(3):412-7. PubMed ID: 2886320
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha,21-dipropionate in human liver and lung homogenate.
Andersson P; Ryrfeldt A
J Pharm Pharmacol; 1984 Nov; 36(11):763-5. PubMed ID: 6150981
[TBL] [Abstract][Full Text] [Related]
13. The effect of budesonide and triamcinolone acetonide on hepatic microsomal testosterone metabolism in the rat.
Edwards RJ; Freeling AB; Watson D; Davies DS
Biochem Pharmacol; 1992 Jan; 43(2):271-82. PubMed ID: 1739415
[TBL] [Abstract][Full Text] [Related]
14. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids.
Dahlberg E; Thalén A; Brattsand R; Gustafsson JA; Johansson U; Roempke K; Saartok T
Mol Pharmacol; 1984 Jan; 25(1):70-8. PubMed ID: 6708937
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships for blood pressure effects of prednisolone in sheep.
Spence CD; Campbell DP; Coghlan JP; Denton DA; Mills EH; Nelson MA; Whitworth JA; Scoggins BA
Clin Exp Hypertens A; 1987; 9(4):773-95. PubMed ID: 3621626
[TBL] [Abstract][Full Text] [Related]
16. Rapid metabolic inactivation of tipredane, a structurally novel topical steroid.
Lan SJ; Scanlan LM; Mitroka J; Weinstein SH; Lutsky BN; Free CA; Wojnar RJ; Millonig RC; Migdalof BH
J Steroid Biochem; 1988 Nov; 31(5):825-34. PubMed ID: 3199821
[TBL] [Abstract][Full Text] [Related]
17. [Glucocorticosteroids: mechanism of action, pharmacological effects, pharmacokinetics and adverse effects].
Tarchalska-Kryńska B
Otolaryngol Pol; 1994; 48 Suppl 17():41-8. PubMed ID: 8090502
[TBL] [Abstract][Full Text] [Related]
18. Is zebrafish (Danio rerio) water tank model applicable for the assessment of glucocorticoids metabolism? The budesonide assessment.
de Araujo ALD; Nunes IKDC; Sardela VF; Pereira HMG; Cabral LM; Anselmo CS
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122826. PubMed ID: 34225244
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of the epimeric glucocorticoid budesonide.
Ryrfeldt A; Edsbäcker S; Pauwels R
Clin Pharmacol Ther; 1984 Apr; 35(4):525-30. PubMed ID: 6705451
[TBL] [Abstract][Full Text] [Related]
20. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver.
Jönsson G; Aström A; Andersson P
Drug Metab Dispos; 1995 Jan; 23(1):137-42. PubMed ID: 7720517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
